Mylan takes another step toward Agila buyout; FDA doesn't like state biosimilar restrictions;

> India's Foreign Investment Promotion Board has given its approval for Mylan's ($MYL) $1.6 billion buyout of Agila Specialties, the sterile injectable business of Strides Arcolab. Story

> Actavis ($ACT) says it has met a legal challenge from Horizon Pharma and Jagotec to its application to make a generic version of the anti-inflammatory drug Rayos. Item

> The FDA is offering some enlightenment about what it is looking for in stability testing data. Story

> The FDA is expressing concerns about state laws to restrict biosimilar use as California becomes the most recent to do so. Story

And Finally... Japanese drugmaker Eisai has been selected by the World Health Organization (WHO) to manufacture diethylcarbamazine citrate for treating the tropical disease lymphatic filariasis and has pledged to provide 2.2 billion tablets from its plant in Vizag, India. Report